SCHEMBL23635944

SCHEMBL23635944

COc1ccc(C(F)(F)F)cc1-c1nnc(NC(=O)OC(C)(C)C)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.53
NPC1 O15118 6/20 0.53
RAB9A P51151 4/20 0.53
HSD17B10 Q99714 7/20 0.48
HPGD P15428 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 6/20 0.47
TP53 P04637 2/20 0.47
CYP1A2 P05177 1/20 0.47
AHR P35869 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
TSHR P16473 1/20 0.45
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
RXFP1 Q9HBX9 2/20 0.43
PKM P14618 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23292636 0.86 KDM4E (0.51) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL27097771 0.85 KDM4E (0.56) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL23635907 0.75 KDM4E (0.50) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL30842170 0.75 KDM4E (0.50) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL23292564 0.74 MGAM (0.64) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL23635946 0.73 KDM4E (0.55) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL30842118 0.73 KDM4E (0.44) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL27097749 0.73 KDM4E (0.44) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL23635973 0.73 SCN9A (0.45) KDM4ENPC1RAB9AHSD17B10HPGD
SCHEMBL30842121 0.72 KDM4E (0.53) KDM4ENPC1RAB9AHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277683-A1 COMPOUNDS CTXT PTY LTD (AU) 2024-08-22 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-20210213004-A1 Compounds CTXT PTY LTD (AU) 2021-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277683-A1 COMPOUNDS SLC10A1, ABCB11, REN KDM4E 4246/4885NPC1 9/4885RAB9A 352/4885
US-20210213004-A1 Compounds SLC10A1, ABCB11, REN KDM4E 3932/4885NPC1 13/4885RAB9A 323/4885
US-11911372-B2 Compounds SLC10A1, ABCB11, REN KDM4E 3932/4885NPC1 13/4885RAB9A 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.